Advertisement
Canada markets close in 2 hours 49 minutes

  • S&P/TSX

    22,036.76
    +164.80 (+0.75%)
     

  • S&P 500

    5,067.49
    +56.89 (+1.14%)
     

  • DOW

    38,491.55
    +251.57 (+0.66%)
     

  • CAD/USD

    0.7321
    +0.0020 (+0.27%)
     

  • CRUDE OIL

    83.04
    +1.14 (+1.39%)
     

  • Bitcoin CAD

    91,214.34
    +508.39 (+0.56%)
     

  • CMC Crypto 200

    1,436.72
    +21.96 (+1.55%)
     

  • GOLD FUTURES

    2,342.80
    -3.60 (-0.15%)
     

  • RUSSELL 2000

    2,003.28
    +35.81 (+1.82%)
     

  • 10-Yr Bond

    4.5780
    -0.0450 (-0.97%)
     

  • NASDAQ

    15,680.16
    +228.86 (+1.48%)
     

  • VOLATILITY

    16.26
    -0.68 (-4.01%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

SomaLogic to Present at the Stifel 2021 Virtual Healthcare Conference

SomaLogic, Inc.
·1 min read

NEW YORK and BOULDER, Colo., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Stifel 2021 Virtual Healthcare Conference.

SomaLogic’s management is scheduled to participate in a fireside chat on Wednesday, November 17, 2021 at 11:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.somalogic.com/events-and-presentations.

About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

The SomaScan Platform is for Research Use Only (RUO) and has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic or patient management purposes.

SomaLogic Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com

Investor Contact
Marissa Bych or Lynn Lewis
Gilmartin Group LLC
investors@somalogic.com